{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-002920","form_type":"8-K","ticker":null,"cik":"0001183765","company_name":"Molecular Templates, Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.565640+00:00","generated_at":"2026-06-01T22:41:23.026485+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Molecular Templates Q1 net income $0.6M on revenue $11.1M; MT-6402 shows 2 PRs in HNSCC","bullets":["Net income $0.6M ($0.11 basic EPS) vs $10.8M ($2.89) in Q1 2023; revenue $11.1M vs $36.6M.","Cash and equivalents $6.8M; subsequent $9.5M financing closing supports ops into Q4 2024.","MT-6402 monotherapy in HNSCC: 2 confirmed PRs (ongoing 10 & 20 months), 4 SDs in 7 evaluable.","MT-8421 Phase 1 dose escalation ongoing; unique Treg depletion pharmacodynamics."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-002920","json":"https://secwatch.observer/filing/0001171843-24-002920.json","markdown":"https://secwatch.observer/filing/0001171843-24-002920.md","text":"https://secwatch.observer/filing/0001171843-24-002920.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1183765/000117184324002920/0001171843-24-002920-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1183765/000117184324002920/f8k_051524.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T22:41:23.026485+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5ffcac3412652628febb958a466661f6616315c6","claim":"Molecular Templates, Inc. reported the first quarter of 2024 ended March 31, 2024 results: revenue $11.1 million, net income $0.6 million, EPS $0.11 per basic share and $0.08 per diluted share.","evidence_excerpt":"a net income attributable to common shareholders of $10.8 million, or $2.89 per basic and diluted share, for the same period in 2023. Revenues for the first quarter of 2024 were $11.1 million, compared to $36.6 million for the same period in 2023. Total research and development expenses for the first quarter of 2024 were $7.4 million, compared with $19.0 million for","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1183765/000117184324002920/0001171843-24-002920-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2024 ended March 31, 2024"},{"label":"Revenue","value":"$11.1 million"},{"label":"Net income","value":"$0.6 million"},{"label":"EPS","value":"$0.11 per basic share and $0.08 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}